Immunosuppression in nonhuman primates

Transplantation Reviews

Volumn 20, Issue 3, 2006, Pages 131-138

  Fechner, John H ^a   Haustein, Silke V ^a   Knechtle, Stuart J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABI 793; ALEMTUZUMAB; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CD3 ANTIBODY; CD4 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CYCLOSPORIN A; DACLIZUMAB; HU5C8; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU5C8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; OKT 4; OKT 8; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSPORT; CYTOMEGALOVIRUS; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; EXPERIENCE; EXPERIMENTAL MODEL; GASTROINTESTINAL TOXICITY; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOMA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MEDICAL RESEARCH; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS DISEASE; PRIMATE; SIMIAN VIRUS 40; WEIGHT REDUCTION;

EID: 33747755413     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.06.005     Document Type: Article

References (78)

1. Thomas J.M., Carver M., Cunningham P., Sash C., Park K., and Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. II. Effects of adjuvant immunosuppressive drugs. Transplantation 47 (1989) 209-215
2. Jonker M., van de Hout Y., Neuhaus P., et al. Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys. Transplantation 66 (1998) 925-927
3. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
4. Cho C.S., Burkly L.C., Fechner Jr. J.H., et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 72 (2001) 587-597
5. Kawai T., Cosimi A.B., Colvin R.B., et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59 (1995) 256-262
6. Wijkstrom M., Kirchhof N., Graham M., et al. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 207 (2005) 117-127
7. Stegall M.D., Chabot J.A., Engelstad K., et al. The effect of cyclosporine on the glucose tolerance of normal monkeys. Transplant Proc 21 (1989) 926-927
8. Schuurman H.J., Slingerland W., Mennninger K., et al. Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. Transpl Int 14 (2001) 320-328
9. Menninger K., Wieczorek G., Riesen S., et al. The origin of cynomolgus monkey affects the outcome of kidney allografts under neoral immunosuppression. Transplant Proc 34 (2002) 2887-2888
10. Todo S., Ueda Y., Demetris J.A., et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery 104 (1988) 239-249
11. Montgomery S.P., Xu H., Tadaki D.K., et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 74 (2002) 1365-1369
12. Wijnen R.M., Ericzon B.G., Tiebosch A.T., Buurman W.A., Grot C.G., and Kootstra G. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int 5 Suppl 1 (1992) S454-S458
13. Kindt M.V., Kemp R., Allen H.L., Jensen R.D., and Patrick D.H. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. Transplant Proc 31 (1999) 3393-3396
14. Schuurman H.J., Menninger K., Audet M., et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 74 (2002) 951-960
15. Fechner Jr. J.H., Dong Y., Hong X., et al. Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids. Transplantation 72 (2001) 581-587
16. Zhong R., Tucker J., Zhang Z., et al. The long-term survival of baboon-to-monkey kidney and liver xenografts. Xenotransplantation 10 (2003) 398-409
17. Ringers J., Haanstra K.G., Kroczek R.A., et al. Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates. Transplantation 73 (2002) 862-866
18. Hirshberg B., Montgomery S., Wysoki M.G., et al. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes 51 (2002) 2135-2140
19. Adams A.B., Shirasugi N., Durham M.M., et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51 (2002) 265-270
20. Koulmanda M., Smith R.N., Qipo A., Weir G., Auchincloss H., and Strom T.B. Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term anti-CD154-based therapy: nonimmunologic graft failure?. Am J Transplant 6 (2006) 687-696
21. Ikonen T.S., Gummert J.F., Hayase M., et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70 (2000) 969-975
22. Dambrin C., Klupp J., Birsan T., et al. Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation 107 (2003) 2369-2374
23. Serkova N., Hausen B., Berry G.J., et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 294 (2000) 323-332
24. Hausen B., Gummert J., Berry G.J., et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation 69 (2000) 488-496
25. Hausen B., Ikonen T., Briffa N., et al. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 69 (2000) 76-86
26. Montgomery S.P., Mog S.R., Xu H., et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant 2 (2002) 381-385
27. Schuurman H.J., Ringers J., Schuler W., Slingerland W., and Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 69 (2000) 737-742
28. Schuurman H.J., Smith H.T., and Cozzi E. Tolerability of cyclophosphamide and methotrexate induction immunosuppression in nonhuman primates. Toxicology 213 (2005) 1-12
29. Borie D.C., Larson M.J., Flores M.G., et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80 (2005) 1756-1764
30. Klupp J., Dambrin C., Hibi K., et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am J Transplant 3 (2003) 817-829
31. Cozzi E., Vial C., Ostlie D., et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 10 (2003) 300-310
32. Poston R.S., Robbins R.C., Chan B., et al. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation 69 (2000) 2005-2013
33. Knechtle S.J., Fechner Jr. J.H., Dong Y., et al. Primate renal transplants using immunotoxin. Surgery 124 (1998) 438-446
34. Morris R.E., Wang J., Blum J.R., et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23 (1991) 19-25
35. Contreras J.L., Eckhoff D.E., Cartner S., et al. Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients. Transplantation 68 (1999) 215-219
36. Taniguchi Y., Frickhofen N., Raghavachar A., Digel W., and Heimpel H. Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol 44 (1990) 244-251
37. Hausen B., Klupp J., Christians U., et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 72 (2001) 1128-1137
38. Previll X., Sick E., Beauchard S., et al. 6-Methylprednisolone does not impair anti-thymocyte globulin (ATG) immunosuppressive activity in non-human primates. Transpl Immunol 9 (2001) 57-61
39. Bartholomew A.M., Powelson J., Sachs D.H., et al. Tolerance in a concordant nonhuman primate model. Transplantation 68 (1999) 1708-1716
40. Thomas J.M., Carver M., Scott J., Williams E., and Thomas F. Effect of rabbit anti-human thymocyte globulin on lymphocyte subpopulations and functions following allotransplantation in the rhesus monkey. Transplantation 27 (1979) 163-170
41. Jonker M., Ringers J., Ossevoort M.A., et al. Long-term kidney graft survival by delayed T cell ablative treatment in rhesus monkeys. Transplantation 73 (2002) 874-880
42. Knechtle S.J., Vargo D., Fechner J., et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 63 (1997) 1-6
43. Wang Z., and Neville Jr. D.M. Expression and characterization of recombinant soluble monkey CD3 molecules: mapping the FN18 polymorphic epitope. Mol Immunol 40 (2004) 1179-1188
44. Thomas J.M., Neville D.M., Contreras J.L., et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 64 (1997) 124-135
45. Powelson J.A., Knowles R.W., Delmonico F.L., et al. CDR-grafted OKT4A monoclonal antibody in cynomolgus renal allograft recipients. Transplantation 57 (1994) 788-793
46. Kanmaz T., Feng P., Torrealba J., et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation 78 (2004) 1002-1007
47. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 154 (1999) 1923-1932
48. Wijkstrom M., Kenyon N.S., Kirchhof N., et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 77 (2004) 827-835
49. Xu H., Elster E.A., Blair P.J., et al. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant 3 (2003) 1350-1354
50. Schroder C., Azimzadeh A.M., Wu G., Price J.O., Atkinson J.B., and Pierson R.N. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 12 (2003) 19-28
51. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 (1997) 8789-8794
52. Kirk A.D., Burkly L.C., Batty D.S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5 (1999) 686-693
53. Preston E.H., Xu H., Dhanireddy K.K., et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 5 (2005) 1032-1041
54. Xu H., Montgomery S.P., Preston E.H., et al. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol 170 (2003) 2776-2782
55. Kanmaz T., Fechner Jr. J.J., Torrealba J., et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 77 (2004) 914-920
56. Pearson T.C., Trambley J., Odom K., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74 (2002) 933-940
57. Adams A.B., Shirasugi N., Jones T.R., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 174 (2005) 542-550
58. Birsan T., Hausen B., Higgins J.P., et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 75 (2003) 2106-2113
59. Kirk A.D., Tadaki D.K., Celniker A., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72 (2001) 377-384
60. Thomas J.M., Carver F.M., Foil M.B., et al. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 36 (1983) 104-106
61. Kawai T., Sogawa H., Koulmanda M., et al. Long-term islet allograft function in the absence of chronic immunosuppression: a case report of a nonhuman primate previously made tolerant to a renal allograft from the same donor. Transplantation 72 (2001) 351-354
62. Chappell D., Beiras-Fernandez A., Hammer C., and Thein E. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 81 (2006) 552-558
63. Bourdage J.S., and Hamlin D.M. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 59 (1995) 1194-1200
64. Rebellato L.M., Gross U., Verbanac K.M., and Thomas J.M. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57 (1994) 685-694
65. Preville X., Flacher M., LeMauff B., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 71 (2001) 460-468
66. Contreras J.L., Wang P.X., Eckhoff D.E., et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 65 (1998) 1159-1169
67. Nooij F.J., Jonker M., and Balner H. Differentiation antigens on rhesus monkey lymphocytes. II. Characterization of RhT3, a CD3-like antigen on T cells. Eur J Immunol 16 (1986) 981-984
68. Neville Jr. D.M., Scharff J., Hu H.Z., et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 19 (1996) 85-92
69. Mourad G.J., Preffer F.I., Wee S.L., et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation 65 (1998) 632-641
70. Davila E., Byrne G.W., LaBreche P.T., et al. T-cell responses during pig-to-primate xenotransplantation. Xenotransplantation 13 (2006) 31-40
71. Allen K.P., Funk A.J., and Mandrell T.D. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. Comp Med 55 (2005) 377-381
72. Gerritsen W.R., Wagemaker G., Jonker M., et al. The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys. Transplantation 45 (1988) 301-307
73. Stebbings R., Stott J., Almond N., et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retroviruses 14 (1998) 1187-1198
74. de Giorgi L., Brent L., Linch D., Nicolaides K., and Rodeck C.H. The inheritance of a Macaca fascicularis red cell antigen detected by CAMPATH-1 antibody. Immunol Lett 15 (1987) 101-103
75. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
76. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 (1991) 561-569
77. Schuler W., Bigaud M., Brinkmann V., et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77 (2004) 717-726
78. Kean L.S., Gangappa S., Pearson T.C., and Larsen C.P. Transplant tolerance in non-human primate: progress, current challenges and unmet needs. AJT 6 (2006) 884-893